HTD1801, one of HighTide’s lead candidates, awarded a grant in China as the ‘National Science and Technology Major Project’ for ‘New Drug Research and Development’ in November 2017. HTD1801 is under development for the treatment of primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH) and hypercholesterolemia.

This award qualifies HTD1801 a priority regulatory review status for the China market. Total grant is $1.25 million.